PedvaxHIB (haemophilus b conjugate vaccine (meningococcal protein conjugate)) / Merck (MSD) - LARVOL DELTA

Haemophilus influenzae Type b Vaccine Immunogenicity in American Indian/Alaska Native Infants. (PubMed, Pediatrics) - "Postdose 1 immunogenicity of Vaxelis was noninferior to PedvaxHIB. Our findings support the use of Vaxelis in AI/AN children, a population with elevated risk of Hib disease."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Use of Haemophilus influenzae Type b-Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (PubMed, MMWR Morb Mortal Wkly Rep) - "Hib vaccination with a monovalent Hib conjugate vaccine consisting of Hib capsular polysaccharide (polyribosylribitol phosphate [PRP]) conjugated to outer membrane protein complex of Neisseria meningitidis serogroup B, PRP-OMP (PedvaxHIB, Merck and Co., Inc.) has historically been preferred for AI/AN infants, who are at increased risk for invasive Hib disease, because it provides substantial protection after the first dose. On June 26, 2024, CDC's Advisory Committee on Immunization Practices (ACIP) recommended that a hexavalent, combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Hib conjugate, and hepatitis B (HepB) vaccine, DTaP-IPV-Hib-HepB (Vaxelis, MSP Vaccine Company) should be included with monovalent PRP-OMP in the preferential recommendation for AI/AN infants because of the PRP-OMP Hib component...For the booster dose of Hib vaccine, no vaccine formulation is preferred for AI/AN children; any Hib vaccine..."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study) (clinicaltrials.gov) - P4 | N=333 | Completed | Sponsor: Johns Hopkins Bloomberg School of Public Health | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming. (PubMed, J Immunother Cancer) - "This work provides rationale for the translation of pathogen vaccines as FDA-approved clinical-grade DC activators which could be exploited as immune-stimulants for early phase trials."

Journal • Immune Modulation • Oncology • CD8

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study) (clinicaltrials.gov) - P4 | N=330 | Active, not recruiting | Sponsor: Johns Hopkins Bloomberg School of Public Health | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases